Clinical Trials Directory

Trials / Unknown

UnknownNCT02764359

Study of Obese Patients Comparing Two Vancomycin Loading Dose Regimens

Single-Center Prospective Study of Obese Patients Comparing Two Vancomycin Loading Dose Regimens

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
128 (estimated)
Sponsor
CAMC Health System · Academic / Other
Sex
All
Age
18 Years – 99 Years
Healthy volunteers
Not accepted

Summary

Obesity alters the movement through the body of several antibiotics, including vancomycin. Based on literature to date, total body weight should be used to determine dosages and shorter dosing intervals may be needed. However, hospitals have different approaches to managing vancomycin in this patient population. The most common example is not exceeding a dose of 2,000mg of vancomycin at one time in these patients. However, some institutions including the Charleston Area Medical Center do not have a set maximum one time dose. To date, a study has not been done comparing two different dosing regimens in obese patients to determine if having a maximum dose cap is beneficial. This research study is attempting to add to the limited existing body of literature regarding vancomycin dosing in obese patients. The investigators hypothesize that optimizing the initial or loading vancomycin dose that obese patients receive will decrease the time to target concentrations. For this study, obese adult patients will be randomized to receive either 1) a loading dose of 20 mg/kg with a maximum dose up to 2,000mg OR 2) a loading dose of 20 mg/kg with a maximum dose of up to 4,000mg. The study's primary aim is to determine differences in the time needed to achieve target vancomycin concentrations and the occurrence of adverse events.

Conditions

Interventions

TypeNameDescription
DRUGIV vancomycinIV vancomycin for the treatment of infection. Following the vancomycin loading dose, vancomycin dosing will be at the discretion of the pharmacist and attending physician and will follow standard of care.

Timeline

Start date
2016-08-01
Primary completion
2021-01-22
Completion
2021-01-22
First posted
2016-05-06
Last updated
2020-02-05

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02764359. Inclusion in this directory is not an endorsement.